significant and predictable csf penetration by iv administered acivicin in monkeys is consistent with observation of cns side effects in patients in the phase i clinical trial and suggests that acivicin should be evaluated in the treatment of cns malignancies and metastases .
C0007806
csf
C3714787
cns